Company Overview
Snapshot
Founded in April 2016 by Shabtai Shoval, Alona Zilberberg, Rotem Ben-Hamo, and Sol Efroni, Hide and Seq operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing an in vitro diagnostic genomic signature.
Business overview
Hide and Seq is a Health Tech & Life Sciences company specializing in personalized cancer treatment. The company develops an in vitro diagnostic genomic signature to identify patients who would benefit from alternative chemotherapy, particularly for metastatic ovarian cancer. Its core technology aims to predict chemotherapy resistance to paclitaxel (Taxol), thereby offering physicians a tailored treatment approach to enhance efficacy and survival. Hide and Seq primarily serves the healthcare industry, focusing on oncology, diagnostics, and women's health.
Strategic signal
In May 2016, Hide and Seq announced a collaboration with AbbVie, signaling external validation of its personalized cancer treatment approach. This partnership highlights the company's potential to integrate its diagnostic genomic signature into broader therapeutic strategies, suggesting a strategic move towards clinical application and market relevance for its predictive assay.
Log in to access full profile ›Company Intelligence Q&A
- When was Hide and Seq founded?
- Hide and Seq was founded in April 2016.
- Who are the founders of Hide and Seq?
- The co-founders of Hide and Seq are Shabtai Shoval, Alona Zilberberg, Rotem Ben-Hamo, and Sol Efroni.
- What is Hide and Seq's primary focus?
- Hide and Seq focuses on developing personalized cancer therapies by combining predictive and prognostic biomarkers to promote effective treatment for various cancer types.
- What is the company's current employee size?
- Hide and Seq currently has 1–10 employees.
- What significant collaboration did Hide and Seq announce?
- In May 2016, Hide and Seq announced a collaboration with AbbVie concerning personalized cancer treatment.